Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.
SCLC,Extensive Stage|SLFN11-positive
DRUG: Niraparib
Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1), Defined as the rate of patients without a PFS event at 3 months after enrolment, From date of enrolment until 3 months post-enrolment
Progression-free survival (PFS), Defined as the time from the date of enrolment until documented progression, From the date of enrolment until last tumour assessment (approximately 25-30 months after the enrolment of the first patient)|Overall survival (OS), Defined as the time from the date of enrolment until death from any cause, From the date of enrolment until death from any cause (approximately 25-30 months after the enrolment of the first patient)|Disease control rate (DCR) by investigator assessment (according to RECIST v1.1), Defined as the rate of patients, among all enrolled patients, that achieve a complete response (CR) or partial response (PR) or stabilisation of disease (SD, at least at week 6) by investigator assessment, approximately 25-30 months after the enrolment of the first patient|Adverse events according to CTCAE v5.0, Adverse events according to CTCAE v5.0 (any-cause as well as treatment-related) including adverse events leading to dose interruptions, withdrawal of protocol treatment and death, From the date of enrolment until last patient last visit (approximately 25- 30 months after enrolment of the first patient)
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.